INS and type 2 diabetes mellitus: These findings collectively suggest a novel regulatory mechanism where Sidt2 KO induced insulin secretion disorders and mediated β-cell dedifferentiation, with potential therapeutic implications for managing β-cell dysfunction in T2DM.